We are maintaining our $13 fair value estimate for Vanda Pharmaceuticals following first-quarter results that were largely consistent with our expectations. We are also maintaining our no-moat rating
* Recommends approval of tasimelteon for non 24-hour sleep-wake disorder from Vanda Pharmaceuticals
Vanda Pharmaceuticals ' second-quarter results were generally consistent with our expectations, as the firm reported reasonable progress for its U
Vanda Pharmaceuticals reported first-quarter results were below our expectations because of significantly higher-than-anticipated operating costs
We're raising our fair value estimate for Vanda VNDA to $10 per share, following the announcement that orphan sleep disorder drug tasimelteon has gained priority review designation
(Reuters) - Shares of Vanda Pharmaceuticals Inc jumped nearly 42 percent on expectations that its sleep disorder drug could reach market earlier than expected after U.S. health regulators said it...
Vanda VNDA reported first-quarter results that matched our expectations for continued stagnant Fanapt growth, countered by lowered operating
Vanda VNDA reported fourth-quarter results that matched our expectations, and our attention remains focused on the upcoming catalysts for
(Reuters) - Vanda Pharmaceuticals Inc said it would stop developing its experimental drug for major depressive disorder after it failed to meet the main goal of improving symptoms in patients in a...
On the heels of a cluster of good news for tasimelteon in a rare body clock disorder, Vanda VNDA reported that its lead pipeline candidate failed to demonstrate efficacy in its second tested indication of depression. In contrast